Rubicon Research Limited (NSE:RUBICON)
India · Delayed Price · Currency is INR 1,351.60
+7.20 (0.54%)
At close: Jun 16, 2026
Rubicon Research Revenue
In the fiscal year ending March 31, 2026, Rubicon Research had annual revenue of 17.54B INR with 36.57% growth. Rubicon Research had revenue of 5.14B in the quarter ending March 31, 2026, with 43.49% growth.
Revenue
17.54B
Revenue Growth
+36.57%
P/S Ratio
12.70
Revenue / Employee
19.42M
Employees
903
Market Cap
222.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 17.54B | 4.70B | 36.57% |
| Mar 31, 2025 | 12.84B | 4.30B | 50.40% |
| Mar 31, 2024 | 8.54B | 4.60B | 116.99% |
| Mar 31, 2023 | 3.94B | 799.52M | 25.50% |
| Mar 31, 2022 | 3.14B | -11.49M | -0.37% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Abbott India | 69.29B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |